HUP0003160A3 - The use of cd40:cd154-binding inhibiting agent for the preparation of pharmaceuticals used for enhancing of tolerance against tissue graft after pangreatic islet tissue transplantation - Google Patents

The use of cd40:cd154-binding inhibiting agent for the preparation of pharmaceuticals used for enhancing of tolerance against tissue graft after pangreatic islet tissue transplantation

Info

Publication number
HUP0003160A3
HUP0003160A3 HU0003160A HUP0003160A HUP0003160A3 HU P0003160 A3 HUP0003160 A3 HU P0003160A3 HU 0003160 A HU0003160 A HU 0003160A HU P0003160 A HUP0003160 A HU P0003160A HU P0003160 A3 HUP0003160 A3 HU P0003160A3
Authority
HU
Hungary
Prior art keywords
pangreatic
enhancing
preparation
inhibiting agent
tolerance against
Prior art date
Application number
HU0003160A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Biogen Idec Ma Inc Cambridge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc Cambridge filed Critical Biogen Idec Ma Inc Cambridge
Publication of HUP0003160A2 publication Critical patent/HUP0003160A2/hu
Publication of HUP0003160A3 publication Critical patent/HUP0003160A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Steroid Compounds (AREA)
  • External Artificial Organs (AREA)
HU0003160A 1997-06-20 1998-06-19 The use of cd40:cd154-binding inhibiting agent for the preparation of pharmaceuticals used for enhancing of tolerance against tissue graft after pangreatic islet tissue transplantation HUP0003160A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5026797P 1997-06-20 1997-06-20
US7726598P 1998-03-09 1998-03-09

Publications (2)

Publication Number Publication Date
HUP0003160A2 HUP0003160A2 (hu) 2001-01-29
HUP0003160A3 true HUP0003160A3 (en) 2002-09-30

Family

ID=26728084

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0003160A HUP0003160A3 (en) 1997-06-20 1998-06-19 The use of cd40:cd154-binding inhibiting agent for the preparation of pharmaceuticals used for enhancing of tolerance against tissue graft after pangreatic islet tissue transplantation

Country Status (21)

Country Link
US (2) US20030072754A1 (enExample)
EP (1) EP1051191B1 (enExample)
JP (1) JP2002506446A (enExample)
KR (1) KR100634847B1 (enExample)
CN (2) CN1195546C (enExample)
AT (1) ATE339966T1 (enExample)
AU (1) AU730763B2 (enExample)
BG (1) BG64976B1 (enExample)
BR (1) BR9810620A (enExample)
CA (1) CA2294154A1 (enExample)
DE (1) DE69835965T2 (enExample)
EA (1) EA002550B1 (enExample)
EE (1) EE9900588A (enExample)
HU (1) HUP0003160A3 (enExample)
IL (1) IL133303A0 (enExample)
IS (1) IS5273A (enExample)
NO (1) NO996275L (enExample)
NZ (1) NZ502052A (enExample)
SK (1) SK180299A3 (enExample)
TR (1) TR199903142T2 (enExample)
WO (1) WO1998058669A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045958A1 (en) * 1998-03-09 1999-09-16 Biogen, Inc. Cd154 blockade therapy for modulation of immune responses to implanted devices
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
AU2001275186A1 (en) * 2000-06-02 2001-12-17 Nicole Kirchhof Immunotherapeutic method to prevent islet cell rejection
IL152316A0 (en) * 2000-06-09 2003-05-29 Bristol Myers Squibb Co Pharmaceutical compositions and kits for treating transplant rejection
JP4667383B2 (ja) * 2003-06-13 2011-04-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド アグリコシル抗ｃｄ１５４（ｃｄ４０リガンド）抗体およびその使用
EA014226B1 (ru) 2004-07-26 2010-10-29 Байоджен Айдек Ма Инк. Антитела к cd154, их фрагменты и способы применения антител и фрагментов
JP2008520235A (ja) * 2004-11-22 2008-06-19 ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド インスリンを産生可能な拡大され、かつ再分化した成体島β細胞の集団およびその作製方法
WO2007047539A2 (en) * 2005-10-14 2007-04-26 Medtronic, Inc. Localized delivery to the lymphatic system
US8636995B2 (en) 2006-08-31 2014-01-28 Cardiac Pacemakers, Inc. Methods and devices to regulate stem cell homing
US8372399B2 (en) 2006-08-31 2013-02-12 Cardiac Pacemakers, Inc. Bispecific antibodies and agents to enhance stem cell homing
US8911739B2 (en) 2009-02-10 2014-12-16 Trustees Of Columbia University In The City Of New York Methods of preventing rejection of transplanted tissue by administering anti-CD40L antibody and dendritic cells loaded with Hsp60sp peptide
US9527912B2 (en) 2010-05-17 2016-12-27 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10147463B2 (en) 2014-12-10 2018-12-04 Nxp Usa, Inc. Video processing unit and method of buffering a source video stream
US9512229B2 (en) * 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
KR101810778B1 (ko) * 2015-06-23 2017-12-20 서울대학교산학협력단 Cd154 결합 폴리펩타이드 및 그 용도
US10986309B2 (en) 2015-06-30 2021-04-20 Nxp Usa, Inc. Video buffering and frame rate doubling device and method
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227298A (en) * 1990-08-17 1993-07-13 The Trustees Of Columbia University In The City Of New York Method for microencapuslation of cells or tissue
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
JP4751493B2 (ja) * 1996-03-20 2011-08-17 ブリストル−マイヤーズ スクイッブ カンパニー Ｇｐ３９／ｃｄ４０およびｃｔｌａ４／ｃｄ２８／ｂ７経路のブロックによって免疫反応を阻止する方法およびそれに使用する組成物

Also Published As

Publication number Publication date
BR9810620A (pt) 2000-10-03
HK1033548A1 (en) 2001-09-07
EA200000058A1 (ru) 2000-08-28
BG104091A (en) 2000-10-31
EP1051191B1 (en) 2006-09-20
CN1261286A (zh) 2000-07-26
EP1051191A2 (en) 2000-11-15
IS5273A (is) 1999-11-26
WO1998058669A3 (en) 1999-04-29
CN1651919A (zh) 2005-08-10
TR199903142T2 (xx) 2000-09-21
EA002550B1 (ru) 2002-06-27
SK180299A3 (en) 2000-06-12
NO996275D0 (no) 1999-12-17
JP2002506446A (ja) 2002-02-26
WO1998058669A2 (en) 1998-12-30
US20030072754A1 (en) 2003-04-17
CA2294154A1 (en) 1998-12-30
ATE339966T1 (de) 2006-10-15
KR100634847B1 (ko) 2006-10-17
NO996275L (no) 2000-02-21
CN1195546C (zh) 2005-04-06
IL133303A0 (en) 2001-04-30
EE9900588A (et) 2000-08-15
KR20010013965A (ko) 2001-02-26
US20070292440A1 (en) 2007-12-20
AU7983098A (en) 1999-01-04
DE69835965D1 (de) 2006-11-02
NZ502052A (en) 2001-01-26
BG64976B1 (bg) 2006-11-30
AU730763B2 (en) 2001-03-15
HUP0003160A2 (hu) 2001-01-29
DE69835965T2 (de) 2007-06-14

Similar Documents

Publication Publication Date Title
HUP0003160A3 (en) The use of cd40:cd154-binding inhibiting agent for the preparation of pharmaceuticals used for enhancing of tolerance against tissue graft after pangreatic islet tissue transplantation
ZA9880B (en) Table for the controlled release of active agents
AU6865298A (en) The use of cryoprotective agent compounds during cryosurgery
IL129423A0 (en) Improved preparation for use as contrast agent
IL148129A0 (en) System of reusable software parts for implementing concurrency and hardware access, and methods of use
SG113402A1 (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
EP1124543A4 (en) REGULATED RELEASE FORMULATION FOR WATER-SOLUBLE DRUGS
ZA981627B (en) Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
ZA971869B (en) Implants with phasewise release of pharmaceutical substance.
HUP0105313A3 (en) Potassium salt of (s)-omeprazole, process for its preparation and pharmaceutical composition containing the same and its use
HUP9800115A3 (en) Use of rifaximin for the preparation of pharmaceutical composition treating diarrhoea from cryptosporidiosis
AU7578598A (en) Controlled release dosage forms containing water soluble drugs
GB9514518D0 (en) Guanidine salt inhibitors of NO synthase and cyclooxygenase
ZA988718B (en) Drug formulation having controlled release of active compound
HUP0002719A3 (en) Controlled release pharmaceutical preparation with ace inhibitor as active agent
HUP9700806A3 (en) Matrix tablet allowing the prolonged release of the sodium salt of tianeptine and process for the preparation thereof
IL125913A0 (en) Pharmaceutical combination preparation of an inhibitor of the sodium/hydrogen exchanger and medicament for the treatment of cardio-vascular diseases
HUP0203471A3 (en) Antithrombotic compound, process for their preparation, pharmaceutical compositions containing them and their use
EP1225971A4 (en) CONTROLLED RELEASE OF SUBSTANCES
ZA973622B (en) Use of forms of hyaluronic acid (HA) for the treatment of cancer.
AU8451498A (en) Methods for the preparation of artificial cellular tissue
AU1786799A (en) Composition for the controlled release of active compounds
HUP0003159A3 (en) The use of n-monosubstituted-3-oxo-4-aza-5alpha-androst-1-en-17betha-carboxamides for the preparation of pharmaceutical compositions
GB2370036B (en) Treatment of chemical munitions agent hydrolysates
IL120005A0 (en) Pharmaceutical compositions for the treatment of the eye